Becton Dickinson and Company (BDX)vsEmbecta Corp (EMBC)
BDX
Becton Dickinson and Company
$180.94
-0.24%
HEALTHCARE · Cap: $48.05B
EMBC
Embecta Corp
$5.29
+1.93%
HEALTHCARE · Cap: $279.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 2107% more annual revenue ($22.48B vs $1.02B). EMBC leads profitability with a 8.6% profit margin vs 4.2%. EMBC trades at a lower P/E of 3.4x. BDX earns a higher WallStSmart Score of 52/100 (C-).
BDX
Buy52
out of 100
Grade: C-
EMBC
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.0%
Fair Value
$202.87
Current Price
$180.94
$21.93 discount
Margin of Safety
-41.7%
Fair Value
$7.10
Current Price
$5.29
$1.81 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Strong operational efficiency at 23.7%
Areas to Watch
Premium valuation, high expectations priced in
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Earnings declined 31.4%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
EMBC carries more volatility with a beta of 0.85 — expect wider price swings.
BDX is growing revenue faster at 5.4% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BDX scores higher overall (52/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?